Prognostic value of CD44 variant expression in primary breast cancer

International Journal of Cancer

Volumn 84, Issue 3, 1999, Pages 209-215

  Foekens, John A ^a,c   Dall, Peter ^b   Klijn, Jan G M ^a   Skroch Angel, Petra ^b   Claassen, Cassandra J C ^a   Look, Maxime P ^a   Ponta, Helmut ^b   Van Putten, Wim L J ^a   Herrlich, Peter ^b   Henzen Logmans, Sonja C ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD44V ANTIGEN;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK;

ADULT; AGED; ANTIGENS, CD44; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EPITOPES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS;

EID: 0033064550     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990621)84:3<209::AID-IJC2>3.0.CO;2-9     Document Type: Article

References (38)

1. BENNETT, K.L., JACKSON, D.G., SIMON, J.C., TANCZOS, E., PEACH, R., MODRELL, B., STAMENKOVIC, I., PLOWMAN, G. and ARUFFO, A, CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J. Cell Biol., 128, 687-698 (1995).
2. DALL, P., HEIDER, K.-H., HEKELE, A., VON MINCKWITZ, G., KAUFMANN, M., PONTA, H. and HERRLICH, P., Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervival epithelium. Cancer Res., 54, 3337-3341 (1994).
3. DALL, P., HEIDER, K.-H., SINN, H.-P., SKROCH-ANGEL, P., ADOLF, G., KAUFMANN, M., HERRLICH, P. and PONTA, H., Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int. J. Cancer, 60, 471-477 (1995).
4. EORTC BREAST CANCER COOPERATIVE GROUP, Revision of the standards for the assessment of hormone receptors in human breast cancer. Europ. J. Cancer, 16, 1513-1515 (1980).
5. FOEKENS, J.A., PORTENGEN, H., VAN PUTTEN, W.L.J., PETERS, H.A., KRIJNEN, H.L.J.M., ALEXIEVA-FIGUSCH, J. and KLIJN, J.G.M., Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res., 49, 5823-5828 (1989).
6. FOX, S.B., GATTER, K.C., SCREATON, G.R., BELL, M.V., BELL, J.I., HARRIS, A.L., SIMMONS, D. and FAWCETT, J., CD44 and cancer screening. Lancet, 342, 548-549 (1993).
7. FRIEDRICHS, K., FRANKE, F., LISBOA, B.-W., KÜGLER, G., GILLE, I., TERPE, H.-J., HÖLZEL, F., MAASS, H. AND GÜNTHERT, U., CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res., 55, 5424-5433 (1995).
8. GÜNTHERT, U. HOFMANN, M., RUDY, W., REBER, S., ZÖLLER, M., HAUSSMANN, I., MATZKU, S., WENZEL, A., PONTA, H. and HERRLICH, P., A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65, 13-24 (1991).
9. GÜNTHERT, U., STAUDER, R., MAYER, B., TERPE, B., FINKE, L. and FRIEDRICHS, K., Are CD44 variant isoforms involved in human tumor progression? Cancer Surv., 24, 19-42 (1995).
10. GURIEC, N., GAIRARD, B., MARCELLIN, L., WILK, A., CALDEROLI, H., RÉNAUD, R., BERGERAT, P. and OBERLING, F., CD44 isoforms with exon v6 and metastasis of primary NoMo breast carcinomas. Breast Cancer Res. Treat., 44, 261-268 (1997).
11. HEFLER, L., TEMPFER, C., HAEUSLER, G., KUCERA, E., MAYERHOFER, K., ZEILLINGER, R., REINHALTER, A. and KAINZ, C., Cytosol concentrations of CD44 isoforms in breast cancer tissues. Int. J. Cancer, 79, 541-545 (1998).
12. HERRLICH, P., ZÖLLER, M., PALS, S.T. and PONTA, H., CD44 splice variants: metastases meet lymphocytes. Immunol. Today, 14, 395-399 (1993).
13. IIDA, N. and BOURGUIGNON, L.Y.W., New CD44 splice variants associated with human breast cancer. J. cell. Physiol., 162, 127-133 (1995).
14. JACKSON, D.G., BELL, J.I., DICKINSON, R., TIMANS, J., SHIELDS, J. and WHITTLE, N., Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J. Cell Biol., 128, 673-685 (1995).
15. JANSEN, R.H.L., JOOSTEN-ACHJANIE, S.R., ARENDS, J.W., VOLOVICS, A., HUPPERETS, P.S.G.J., SCHOUTEN, H.C. and HILLEN, H.F.P., CD44v6 is not a prognostic factor in primary breast cancer. Ann. Oncol., 9, 109-111 (1998).
16. JOENSUU, H., KLEMI, P.J., TOIKKANEN, S. and JALKANEN, S., Glycoprotein CD44 expression and its association with survival in breast cancer. Amer. J. Pathol., 143, 867-874 (1993).
17. KAUFMANN, M., HEIDER, K-H., SINN, H.P., VON MINCKWITZ, G., PONTA, H. and HERRLICH, P., CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345, 615-619 (1995).
18. LAMB, R.F., HENNIGAN, R.F., TURNBULL, K., KATSANAKIS, K.D., MACKENZIE, E.D., BIRNIE, G.D., and OZANNE, B.W., AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol. cell. Biol., 17, 963-976 (1997).
19. MARTIN, S., JANSEN, F., BOKELMANN, J. and KOLB, H., Soluble CD44 splice variants in metastasizing human breast cancer. Int. J. Cancer, 74, 443-445 (1997).
20. MATSUMURA, T. and TARIN, D., Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340, 1053-1058 (1992).
21. MATSUMURA, T., HANBURY, D., SMITH, J. and TARIN, D., Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. Brit. med. J., 308, 619-624 (1994).
22. NAOR, D., SIONOV, R.V. and ISH-SHALOM, D., CD44: structure, function, and association with the malignant process. Adv. Cancer Res., 71, 241-319 (1997).
23. REBER, S., MATZKU, S., GÜNTHERT, U., PONTA, H., HERRLICH, P. and ZÖLLER, M., Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies. Int. J. Cancer, 46, 919-927 (1990).
24. SCHUMACHER, U., HORNY, H.P., HORST, H.A., HERRLICH, P. and KAISERLING, E., A CD44 variant epitope as a prognostic indicator in breast cancer. Europ. J. Surg. Oncol., 22, 259-261 (1996).
25. SEITER, S., ARCH, R., REBER, S., KOMITOWSKI, D., HOFMANN, M., PONTA, H., HERRLICH, P., MATZKU, S. and ZÖLLER, M., Prevention of tumor metastasis formation by anti-variant CD44. J. exp. Med., 177, 443-455 (1993).
26. SHERMAN, L., SLEEMAN, J., HERRLICH, P. and PONTA, H., Hyalorunate receptors: key players in growth, differentiation, migration and tumor progression. Curr. Opin. Cell. Biol., 6, 726-733 (1994).
27. SHERMAN, L., WAINWRIGHT, D., PONTA, H. and HERRLICH, P., A splice variant of CD44 expressed in the apical ectodermal ridge presents fribroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Develop., 12, 1058-1071 (1998).
28. SINN, H.-P., HEIDER, K.-H., SKROCH-ANGEL, P., VON MINCKWITZ, G., KAUFMANN, M., HERRLICH, P. and PONTA, P., Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res. Treat., 36, 307-313 (1995).
29. SLEEMAN, J.P., KONDO, K., MOLL, J., PONTA, H., and HERRLICH, P., Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44. J. biol. Chem., 272, 31837-31844 (1997).
30. TANABE, K., ELLIS, L. and SAYA, H., Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet, 341, 725-726 (1993).
31. TAHER, T.E., SMIT, L.,. GRIFFIOEN, G.W., SCHILDER-TOL, E.J., BORST, J., and PALS, S.T., Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes. J. biol. Chem., 271, 2863-2867 (1996).
32. TEMPFER, C., LÖSCH, A., HEINZL, H., HÄUSLER, G., HANZAL, E., KÖLBL, H., BREITENECKER, G. and KAINZ, CH., Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Europ. J. Cancer, 32A, 2023-2025 (1996).
33. TOKUE, Y., MATSUMURA, Y., KATSUMATA, N., WATANABE, T., TARIN, D. and KAKIZOE, T., CD44 variant isoform expression and breast cancer prognosis. Jpn. J. Cancer Res., 89, 283-290 (1998).
34. UNDERHILL, C., CD44: the hyaluronan receptor. J. Cell Sci., 103, 293-298 (1992).
35. WAINWRIGHT, D., SHERMAN, L., SLEEMAN, J., PONTA, H. and HERRLICH, P., A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb outgrowth. Ann. N. Y. Acad. Sci., 785, 345-349 (1996).
36. WIELENGA, V.J., HEIDER, K.H., OFFERHAUS, G.J., ADOLF, G.R., VAN DEN BERG, B.M., PONTA, H., HERRLICH, P. and PALS, S.T., Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res., 53, 4754-4756 (1993).
37. YU, Q., and TOOLE, B.P., A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J. biol. Chem., 271, 20603-20607 (1996).
38. YU, Q., TOOLE, B.P., and STAMENKOVIC, I., Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. exp. Med., 186, 1985-1996 (1997).